D&D Pharmatech
4th Floor, 27, Geumto-ro 80beon-gil, Sujeong-gu, Seongnam-si, Seongnam-si, Gyeonggi-do, 13453, South Korea
Overview
D&D Pharmatech is a operator of a holding company created to fund the development of therapeutic medicines through disease-specific subsidiary companies founded and guided by top-tier medical research faculty. The company's product pipeline focuses on a range of indications including neurodegenerative, metabolic and fibrotic diseases, providing the opportunity to accelerate the translation of cutting-edge research into lifesaving therapeutic products for patients.
- Total investments
- 2
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 3
Sector focus
- Biotechnology
- Health Care
- Pharmaceutical
Investment portfolio
- Valted Seq
Participated · Seed · Nov 2021
Valted Seq develops the HiF-Seq platform to collect single-cell and single-nuclei sequencing data from high-quality, clinically characterized post-mortem brain tissues of patients with neurodegenerative diseases such as Parkinson’s and Alzheimer’s. The company is building what it describes as the world’s largest transcriptomic repository from clinically characterized brain tissues to identify disease pathways, validated drug targets and biomarkers. Valted Seq also is developing minimally invasive assays to detect poly (ADP-ribose) (PAR) in CSF, serum and serum-derived exosomes and to assess c-Abl pathway molecules for diagnosing Parkinson’s and related α‑synucleinopathies. Those proprietary assays are intended for high specificity and potential use in clinical trials for target engagement, patient selection and as companion diagnostics. The company intends to partner with biopharmaceutical companies to commercialize and broadly leverage the HiF-Seq dataset and assays. Valted Seq was co-founded in 2019 and is headquartered in Gaithersburg, Md.; Nina Urban is serving as interim CEO.
- Neuraly
Led · Series A · Jul 2018
Neuraly is focused on developing disease‑modifying agents for neurodegenerative disorders, primarily Parkinson’s and Alzheimer’s disease. Its lead program, NLY01, is a brain‑penetrant, long‑acting GLP‑1 receptor agonist that showed neuroprotective effects in preclinical models, including inhibition of microglial activation, prevention of neuronal death, slowed disease progression, improved motor and cognitive function, and extended lifespan in Parkinson’s models. NLY01 leverages a GLP‑1R class safety profile documented by approved diabetes treatments, and Neuraly expected to initiate a Phase 1 clinical trial in 2018. The company was formed in 2016 based on Johns Hopkins research and holds exclusive licenses to related patents; supporting data were published in Nature Medicine. Neuraly also reports two additional early‑stage pipeline candidates targeting complementary mechanisms. The company launched alongside a Series A financing to fund clinical development.